Lactose (India) Limited has announced the adoption of a new business line in specialized pharmaceutical excipients, marking a strategic expansion into value-added products. The company disclosed this development to BSE Limited under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

New Business Line Details

The company has expanded into value-added pharmaceutical excipients, specifically specialized grades of pharmaceutical lactose, which fall under the pharmaceutical and healthcare raw materials/excipients industry. This strategic move represents a significant shift towards higher-value products in the pharmaceutical sector.

Expected Benefits and Strategic Rationale

The expansion is expected to deliver multiple strategic advantages for the company:

• Expansion of the company's value-added product portfolio
• Reduction in dependence on imported specialized lactose products
• Improved margin profile compared to regular pharma grade lactose
• Strengthening of long-term relationships with pharmaceutical customers
• Complete product basket enabling customer retention and reduced import dependency

The expansion aligns with the company's strategy to move up the value chain, cater to specialized pharmaceutical requirements, and support domestic manufacturing under import substitution initiatives.

Product Portfolio Launch

Lactose India has successfully developed and launched four specialized pharmaceutical excipient products:

Market Deployment and Timeline

The company has successfully completed internal development and trial runs of all products. Selective supplies to customers have commenced, following customer-specific validation and acceptance requirements. The products are primarily intended for the domestic pharmaceutical market, though the company may explore international markets subject to commercial feasibility and applicable regulatory requirements.

This development represents Lactose India's commitment to expanding its specialized product offerings and reducing India's dependence on imported pharmaceutical excipients while strengthening its position in the domestic pharmaceutical supply chain.

Lactose (India) Limited has received comprehensive regulatory filings from SST Private Family Trust regarding its completed acquisition of a 4.57% stake in the pharmaceutical company. The trust filed detailed disclosure documents with SEBI on January 14, 2026, following the completion of the inter-se transfer among promoter group entities on December 17, 2025.

SEBI Regulatory Filing Details

SST Private Family Trust submitted its mandatory disclosure under Regulation 10(7) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The comprehensive filing included all required regulatory documentation:

Transaction Completion Summary

The acquisition involved the transfer of shares from Madhusha Lifecare Private Limited to SST Private Family Trust, both being promoter group entities. The transaction was executed at a predetermined price with full regulatory compliance:

Shareholding Pattern Changes

The completed transaction resulted in significant changes to SST Private Family Trust's shareholding position while maintaining overall promoter group holdings:

Regulatory Compliance Timeline

The trust maintained full compliance with SEBI regulations throughout the acquisition process, filing all required documents within prescribed timelines:

Demat Account Clarification

SST Private Family Trust operates two demat accounts under different names but belonging to the same trust entity. Due to a clerical error, shares were transferred to the account reflecting the Trustee's name (Mahendra Singhi) instead of the Settlor's name (Shyamsunder Bhorilal Toshniwal) as initially indicated. The trust clarified that both accounts belong to the same entity and no third-party transfer occurred.

The transaction falls under the general exemption provisions of Regulation 10(1)(a) of SEBI SAST Regulations, covering inter-se transfers among promoter group entities and immediate relatives. The aggregate holding of the promoter and promoter group remains unchanged, with the transaction representing an internal restructuring within the promoter group of the pharmaceutical company.